These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 32410705

  • 1. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
    Skriver SK, Jensen MB, Knoop AS, Ejlertsen B, Laenkholm AV.
    Breast Cancer Res; 2020 May 14; 22(1):46. PubMed ID: 32410705
    [Abstract] [Full Text] [Related]

  • 2. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH, Li CX, Liu M, Jiang JY.
    BMC Cancer; 2020 Nov 25; 20(1):1150. PubMed ID: 33238978
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T, Hida AI, Inoue N, Imamura M, Fujimoto Y, Akazawa K, Hirota S, Miyoshi Y.
    Breast Cancer Res Treat; 2018 Feb 25; 168(1):135-145. PubMed ID: 29168063
    [Abstract] [Full Text] [Related]

  • 9. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
    Park JH, Kang MJ, Ahn JH, Kim JE, Jung KH, Gong G, Lee HJ, Son BH, Ahn SH, Kim HH, Shin HJ, Moon DH, Kim SB.
    Cancer Chemother Pharmacol; 2016 Oct 25; 78(4):685-95. PubMed ID: 27491481
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
    Meisel JL, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X.
    Clin Breast Cancer; 2020 Feb 25; 20(1):19-24. PubMed ID: 31806448
    [Abstract] [Full Text] [Related]

  • 11. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
    Gahlaut R, Bennett A, Fatayer H, Dall BJ, Sharma N, Velikova G, Perren T, Dodwell D, Lansdown M, Shaaban AM.
    Eur J Cancer; 2016 Jun 25; 60():40-8. PubMed ID: 27062316
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E.
    Lancet Oncol; 2019 Sep 25; 20(9):1226-1238. PubMed ID: 31402321
    [Abstract] [Full Text] [Related]

  • 13. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
    Rusz O, Vörös A, Varga Z, Kelemen G, Uhercsák G, Nikolényi A, Ormándi K, Simonka Z, Kahán Z.
    Pathol Oncol Res; 2015 Sep 25; 21(4):977-84. PubMed ID: 25753983
    [Abstract] [Full Text] [Related]

  • 14. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.
    Asian Pac J Cancer Prev; 2012 Sep 25; 13(8):4119-23. PubMed ID: 23098527
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Kochi M, Iwamoto T, Niikura N, Bianchini G, Masuda S, Mizoo T, Nogami T, Shien T, Motoki T, Taira N, Tokuda Y, Doihara H, Matsuoka J, Fujiwara T.
    Breast Cancer Res Treat; 2018 Jan 25; 167(1):39-47. PubMed ID: 28905250
    [Abstract] [Full Text] [Related]

  • 17. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM, Harhay MO, Zhang P, Ugras S.
    Ann Surg Oncol; 2018 Nov 25; 25(12):3535-3540. PubMed ID: 29981025
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
    Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stöger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Maria Tea MK, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M, Austrian Breast & Colorectal Cancer Study Group.
    Eur J Cancer; 2020 Jun 25; 132():43-52. PubMed ID: 32325419
    [Abstract] [Full Text] [Related]

  • 19. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
    Jang N, Kwon HJ, Park MH, Kang SH, Bae YK.
    Ann Surg Oncol; 2018 Apr 25; 25(4):937-946. PubMed ID: 29330719
    [Abstract] [Full Text] [Related]

  • 20. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD, Nassar A, Siddiqui MT, Cohen C.
    Int J Clin Exp Pathol; 2012 Apr 25; 5(6):530-6. PubMed ID: 22949935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.